Aztreonam lysine (Cayston®) is recommended as an option for restricted use within NHS Wales. Aztreonam lysine (Cayston®) should be restricted for third-line use in the following subpopulation within its licensed indication for suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis aged six years and older:

• Patients in whom nebulised colistimethate sodium and nebulised tobramycin are not tolerated or are not providing satisfactory therapeutic benefit.

Aztreonam lysine (Cayston®) is not recommended for use within NHS Wales outside of this subpopulation. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.